9/22
08:08 am
gri
GRI Bio (NASDAQ:GRI) had its price target raised by analysts at Ascendiant Capital Markets from $34.00 to $35.00. They now have a "buy" rating on the stock.
Medium
Report
GRI Bio (NASDAQ:GRI) had its price target raised by analysts at Ascendiant Capital Markets from $34.00 to $35.00. They now have a "buy" rating on the stock.
9/11
09:31 am
gri
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) [Yahoo! Finance]
Medium
Report
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) [Yahoo! Finance]
9/11
08:45 am
gri
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
High
Report
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)